Ulcerative pyoderma gangrenosum is a rare disease with ... Vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, blocks the C5a activity, leaving the c5b-9 membrane ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal ... to vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG), a rare skin disorder characterized by ...

No one knows the cause of pyoderma gangrenosum. It causes painful skin ulcers, usually on the legs, occasionally on the hands. The ulcers can form after an insect bite or some other minor skin ...

Abnormalities in the PTPN6 gene have been implicated in human diseases such as pyoderma gangrenosum, multiple sclerosis, leukemia and psoriatic arthritis. The researchers used a strain of gene ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody ... Phase II results in ANCA-associated vasculitis and pyoderma gangrenosum. Vilobelimab is in Phase III ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody ... threatening inflammatory indications, including pyoderma gangrenosum.